Mañes S - Search Results

1

CCR5 as a potential target in cancer therapy: inhibition or stimulation?

González-Martin A, Mira E, Mañes S. González-Martin A, et al. Among authors: manes s. Anticancer Agents Med Chem. 2012 Nov;12(9):1045-57. doi: 10.2174/187152012803529637. Anticancer Agents Med Chem. 2012. PMID: 22583417 Review.

2

Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells.

González-Martín A, Gómez L, Lustgarten J, Mira E, Mañes S. González-Martín A, et al. Among authors: manes s. Cancer Res. 2011 Aug 15;71(16):5455-66. doi: 10.1158/0008-5472.CAN-11-1687. Epub 2011 Jun 29. Cancer Res. 2011. PMID: 21715565

3

Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection.

Luis Abad J, González MA, del Real G, Mira E, Mañes S, Serrano F, Bernad A. Luis Abad J, et al. Among authors: manes s. Mol Ther. 2003 Sep;8(3):475-84. doi: 10.1016/s1525-0016(03)00202-8. Mol Ther. 2003. PMID: 12946321 Free article.

4

Immunomodulatory and anti-inflammatory activities of statins.

Mira E, Mañes S. Mira E, et al. Among authors: manes s. Endocr Metab Immune Disord Drug Targets. 2009 Sep;9(3):237-47. doi: 10.2174/187153009789044383. Epub 2009 Sep 1. Endocr Metab Immune Disord Drug Targets. 2009. PMID: 19594418 Review.

5

CCR5 in cancer immunotherapy: More than an "attractive" receptor for T cells.

González-Martín A, Mira E, Mañes S. González-Martín A, et al. Among authors: manes s. Oncoimmunology. 2012 Jan 1;1(1):106-108. doi: 10.4161/onci.1.1.17995. Oncoimmunology. 2012. PMID: 22720226 Free PMC article.

6

CCR5 expression influences the progression of human breast cancer in a p53-dependent manner.

Mañes S, Mira E, Colomer R, Montero S, Real LM, Gómez-Moutón C, Jiménez-Baranda S, Garzón A, Lacalle RA, Harshman K, Ruíz A, Martínez-A C. Mañes S, et al. J Exp Med. 2003 Nov 3;198(9):1381-9. doi: 10.1084/jem.20030580. J Exp Med. 2003. PMID: 14597737 Free PMC article.

7

The Chemokine Receptor CCR5 Links Memory CD4⁺ T Cell Metabolism to T Cell Antigen Receptor Nanoclustering.

Blanco R, Gómez de Cedrón M, Gámez-Reche L, Martín-Leal A, González-Martín A, Lacalle RA, Ramírez de Molina A, Mañes S. Blanco R, et al. Among authors: manes s. Front Immunol. 2021 Dec 7;12:722320. doi: 10.3389/fimmu.2021.722320. eCollection 2021. Front Immunol. 2021. PMID: 34950130 Free PMC article.

8

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

Caffarel MM, Andradas C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G, Flores JM, García-Real I, Palacios J, Mañes S, Guzmán M, Sánchez C. Caffarel MM, et al. Among authors: manes s. Mol Cancer. 2010 Jul 22;9:196. doi: 10.1186/1476-4598-9-196. Mol Cancer. 2010. PMID: 20649976 Free PMC article.

9

CX3CL1 promotes breast cancer via transactivation of the EGF pathway.

Tardáguila M, Mira E, García-Cabezas MA, Feijoo AM, Quintela-Fandino M, Azcoitia I, Lira SA, Mañes S. Tardáguila M, et al. Among authors: manes s. Cancer Res. 2013 Jul 15;73(14):4461-73. doi: 10.1158/0008-5472.CAN-12-3828. Epub 2013 May 29. Cancer Res. 2013. PMID: 23720051 Free PMC article.

10

A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors.

Mira E, Carmona-Rodríguez L, Tardáguila M, Azcoitia I, González-Martín A, Almonacid L, Casas J, Fabriás G, Mañes S. Mira E, et al. Among authors: manes s. Oncotarget. 2013 Dec;4(12):2288-301. doi: 10.18632/oncotarget.1376. Oncotarget. 2013. PMID: 24317954 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page